ArticleCancer causes & control : CCC2023
Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012-2018.
Article in Cancer causes & control : CCC, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The Role of Health Literacy in Skin Cancer Preventative Behavior and Implications for Intervention: A Systematic Review.Journal of prevention (2022) · 2024Pooled it
- Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- Implementation of an Occupational Sun Safety Intervention: A Comparison of Two Scalability Strategies.Journal of occupational and environmental medicine · 2025Trial
- Awareness and Use of the Ultraviolet Index Among U.S. Adults.Health education & behavior : the official publication of the Society for Public Health Education · 2026Article
- Occupational Pesticide Exposure and Risk of Non-melanoma Skin Cancer Among U.S. Adults: A Systematic Review.Cureus · 2026Review
- Economic evaluation of added neoadjuvant cemiplimab to upfront wide local excision for advanced cutaneous squamous cell carcinoma of the head and neck.JID innovations : skin science from molecules to population health · 2026Article
- Machine learning-guided bioelectrical impedance mapping for rapid adjunctive margin assessment in Mohs surgery.npj biomedical innovations · 2026Article
- Skin Cancer Awareness and Sun Safety Practices Among California Surfers.JAAD international · 2026Article
- Article
- Skin Cancer Predisposition Genes, Full-Body Skin Examinations, Familial Disclosure, and Genetic Testing Among High-Risk Individuals.International journal of dermatology · 2026Article
- Microneedle-based theranostics for melanoma: Advances and outlook.Materials today. Bio · 2026Review
- Sunburn Prevalence Among US High School Students, Youth Risk Behavior Survey, United States, 2023.Preventing chronic disease · 2026Article
- Immunotherapy for early-stage cutaneous squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Review
- Prevalence and Context of Sunburn Among U.S. Adults - United States, 2024.MMWR. Morbidity and mortality weekly report · 2026Article
- How is Artificial Intelligence Transforming the Skin Cancer Screening Pathway? An Umbrella Review.Research square · 2026Article
- Explainable and secure federated learning for privacy-enhancing skin cancer classification using a lightweight multi-scale CNN.Scientific reports · 2026Article
- [Chronic skin damage from UV radiation].Dermatologie (Heidelberg, Germany) · 2026Review
- Intraoperative margin assessment in keratinocyte skin cancer: Evolving techniques and future directions.CytoJournal · 2026Article
- Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- Skin Cancer Surveillance Program for Solid Organ Transplant Recipients.JAMA dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeWe report the prevalence and economic cost of skin cancer treatment compared to other cancers overall in the USA from 2012 to 2018.
methodsUsing the Medical Expenditure Panel Survey full-year consolidated data files and associated medical conditions and medical events files, we estimate the prevalence, total costs, and per-person costs of treatment for melanoma and non-melanoma skin cancer among adults aged ≥ 18 years in the USA. To understand the changes in treatment prevalence and treatment costs of skin cancer in the context of overall cancer treatment, we also estimate the prevalence, total costs, and per-person costs of treatment for non-skin cancer among US adults.
resultsDuring 2012-15 and 2016-18, the average annual number of adults treated for any skin cancer was 5.8 (95% CI: 5.2, 6.4) and 6.1 (95% CI: 5.6, 6.6) million, respectively, while the average annual number of adults treated for non-skin cancers rose from 10.8 (95% CI: 10.0, 11.5) to 11.9 (95% CI: 11.2, 12.6) million, respectively. The overall estimated annual costs rose from $8.0 (in 2012-2015) to $8.9 billion (in 2016-18) for skin cancer treatment and $70.2 to $79.4 billion respectively for non-skin cancer treatment.
conclusionThe prevalence and economic cost of skin cancer treatment modestly increased in recent years. Given the substantial cost of skin cancer treatment, continued public health attention to implementing evidence-based sun-safety interventions to reduce skin cancer risk may help prevent skin cancer and the associated treatment costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.